ZK 159222
目录号 : GC48271An antagonist of the vitamin D receptor
Cas No.:156965-15-0
Sample solution is provided at 25 µL, 10mM.
ZK 159222 is an antagonist of the vitamin D receptor (VDR).1,2 It stabilizes the VDR in an antagonistic conformation that prevents interaction with coactivator proteins.3 ZK 159222 inhibits VDR-mediated target gene activation when used at concentrations of 300 and 1,000 nM in reporter assays. Preincubation of preadipocytes with ZK 159222 (0.01 and 1 µM) decreases the secretion of IL-1β, IL-6, IL-8, CCL2, and RANTES induced by macrophage-conditioned medium (MacCM).4 It also decreases the secretion of these cytokines in preadipocytes prestimulated with MacCM and decreases MacCM-induced phosphorylation of p44/42 and p38 MAPK in preadipocytes.
1.Herdick, M., Steinmeyer, A., and Carlberg, C.Antagonistic action of a 25-carboxylic ester analogue of 1ɑ,25-dihydroxyvitamin D3 is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivatorsJ. Biol. Chem.275(22)16506-16512(2000) 2.Herdick, M., Steinmeyer, A., and Carlberg, C.Carboxylic ester antagonists of 1ɑ,25-dihydroxyvitamin D3 show cell-specific actionsChem. Biol.7(11)885-894(2000) 3.Bury, Y., Steinmeyer, A., and Carlberg, C.Structure activity relationship of carboxylic ester antagonists of the vitamin D3 receptorMol. Pharmacol.58(5)1067-1074(2000) 4.Zhu, J., and Wilding, J.P.H.The 1α,25(OH)2D3 analogs ZK159222 and ZK191784 show anti-inflammatory properties in macrophage-induced preadipocytes via modulating the NF-κB and MAPK signalingDiabetes Metab. Syndr. Obes.131715-1724(2020)
Cas No. | 156965-15-0 | SDF | |
Canonical SMILES | C=C1/C(C[C@@H](O)C[C@@H]1O)=C\C=C2CCC[C@@]3(C)[C@@]/2([H])CC[C@]3([H])[C@H](C)/C=C/[C@@H](O)C4(CC4)C(OCCCC)=O | ||
分子式 | C32H48O5 | 分子量 | 512.7 |
溶解度 | DMSO : 100 mg/mL (195.04 mM; Need ultrasonic) | 储存条件 | 4°C, protect from light, stored under nitrogen |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.9505 mL | 9.7523 mL | 19.5046 mL |
5 mM | 0.3901 mL | 1.9505 mL | 3.9009 mL |
10 mM | 0.195 mL | 0.9752 mL | 1.9505 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet